Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody
... data demonstrating potent anti-cancer activity in colon
and breast cancer models for the company's first ... and a co-author of the paper. "In models of colon
and breast cancer, we observed that treatment ... decreases the ratio of cancer stem cells found in colon
and breast tumors. Notably, treatment with ...
Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
... remain on track to make our new Onco type DX colon
cancer test available early in 2010."
... positive results from the landmark QUASAR colon
cancer validation study at the 2009 ASCO annual ... Results demonstrated that the Onco type DX colon
cancer test can independently predict individual ...
AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
... targets of both multiple myeloma and metastatic colon
cancer where, unlike the non-small cell lung ... Phase 2 data for multiple myeloma and metastatic colon
cancer were presented at ASH and ASCO meeting, ... with capecitabine for advanced metastatic colon
cancer (placebo-controlled), as well as for ...
Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay
... predict the likelihood of recurrence for stage II colon
cancer patients following surgery, and that the colon
cancer Recurrence Score(R) provided additional ... commercialization plans to make the Onco type DX colon
cancer Recurrence Score available to physicians ...
Anti-cancer gene discovered: Perspective for therapy
... of those genes, Atonal homolog 1 or ATOH1, causes colon
cancer. The gene regulates the last step in the ... to epithelial cell of the colon. Humans with colon
cancer frequently have an inactivated ATOH1 gene, ... in a test tube reactivate the gene in human colon
cancer cells. The tumor cells stopped growing and ...
Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon
... colorectal cancers (CRCs) on the left side of the colon
and 40-67 percent of the CRCs on the right side ... of patients had polyps on the right-side of the colon
vs. the left side.
The Third Eye Retroscope ... the physician with an additional view of the colon
for diagnostic and detection purposes. When the ...
Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum
... of colorectal
cancer. If treated early, 90% of colon
cancer patients survive. The humane,
medical, and financial impact of an effective, non-invasive colon
screening test can not be overstated."
Over 90 million Americans are at risk for colon
cancer, a disease that
kills 50,000 Americans ...
Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
... validation study for its 18-gene Oncotype DX(R) colon
cancer assay. Utilizing more than 1,200 patient ... to assess the clinical utility of the Oncotype DX colon
cancer assay to predict likelihood of recurrence for stage II colon
cancer patients treated with surgery alone and ...
Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing
... a non-invasive test
for the early detection of colon
cancer, which will be made available as ... have an important impact on the
epidemiology of colon
cancer, one of the main causes of cancer ... for the non-invasive detection of colon
Rosetta Genomics Reports Second Quarter 2008 Financial Results
... is being
developed to detect the presence of colon
cancer in serum, the second is
being developed to ... and the third is
being developed to predict colon
cancer risk of recurrence after surgery.
Rosetta ... identified microRNA biomarkers in the serum of colon
cancer patients which may serve as the basis for ...
MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
... the clinical validation of Medicsight's colon
CAD products set in
the context of the world's ... agreed to integrate
Medicsight ColonCAD into its colon
solution for global distribution. As
well as ... was granted
regulatory approval for MedicRead colon
from the Chinese State Food and
Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
... Unique microRNA Biomarkers in the
Serum of colon
Cancer Patients, Which may Serve as the Basis for a Future Test for colon
New Tests Expected to be Developed and ... identified microRNA
biomarkers in the serum of colon
cancer patients which may serve as the
basis for ...
MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Administration ("SFDA") for our MedicRead colon
workstation, and we plan to
launch this ... Administration ("SFDA") for its MedicRead colon
workstation. Medicsight will launch this ... analyze suspicious pathology within the colon
and lungs. The Medicsight
CAD products are ...
Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
... benefit for early-stage (stage II and III) colon
cancer. -- Based on multiple clinical studies ... of an 18-gene panel for our Oncotype DX colon
cancer assay, which is now undergoing analytical ... the results of studies related
to early-stage colon
cancer, and our ability to develop a clinical ...
Colon Cancer Screening Laws Now Cover Half of U.S. Population
... insurance providers to cover the cost of colon
tests, according to a new report ... insurance carriers to pay for
the full range of colon
cancer screening tests, including colonoscopy. ... by laws that require insurance coverage for colon
compared to 49 percent at the ...
Vaccinogen's New Anti-Cancer Vaccine Commercially Available in Europe This Year
... Inc. announced that
its new vaccine to block colon
cancer from recurring will be ... the world's first commercially viable vaccine
cancer," said Dr. Michael G. Hanna, Jr., Ph.D., ... provides us and
the growing population of colon
cancer patients in Eastern Europe."
Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
... (PCT) for the extraction
of proteins from colon
cancer tissues was presented on Sunday, October ... of the Brooklyn Hospital Center. colon
cancer is the second leading cause of cancer ... signature protein (hCG1787564)
extracted from colon
tumor tissue by PCT might be a biomarker that ...
Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Society's 29th Annual Meeting
... surrounding stroke, (2) detect
biomarkers of colon
cancer, and (3) detect proteins associated with ... we are attempting to
discover new biomarkers of colon
cancer, in an effort to develop better
surgical ... of new therapeutics and diagnostics for stroke, colon
and embryo viability; that due to ...
New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation
... for patients who have
adjuvant stage III colon
cancer and advanced colorectal cancer, which ... is indicated for
adjuvant treatment of stage III colon
cancer patients who have undergone
complete ... II, the cancer has grown through the wall of the colon
rectum but has not yet spread to nearby lymph ...
Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
... cancer test, Genomic Health is preparing to launch its Onco type DX colon
cancer test in early 2010. The company was founded in 2000 and is located ... policies in Europe, and the company's plans to commercialize a test for colon
cancer and the proposed timing of such commercialization. Forward-looking ...
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
... It is a serious illness caused by infection of the inner lining of the colon
by C. difficile bacteria, which produce toxins that cause inflammation ... may facilitate the return of the normal physiological conditions in the colon
and reduce the probability of CDI recurrence.
About Optimer ...
Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR
... Angiopoietin (Ang) 1 and
Ang2 on the tumor vasculature of a human colon
(Colo205) using peptide-Fc fusion proteins ... breast, head and neck, lung,
brain, prostate, cervix, liver, colon
Lead author: Swift S.
Abstract No. 4283 ...
Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
... R. et al. (2009). Highly efficient lysis of KRAS- and BRAF-mutated human colon
cancer cells by T cell-engaging BiTE antibodies derived from anti-EGFR ... B-F, poster section 12.
Muenz, M. et al. (2009). Eradication of colon
cancer stem cells by EpCAM/CD3-bispecific BiTE antibody MT110. AACR Annual ...
ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program
... the European
Economic Union, including France, Germany and the U.K.
cancer is the second most common form of cancer in Europe. In 2004,
376,400 people contracted the illness while 203,700 colon
died. Despite considerable progress in treatment, the ...
AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives
... hospitals to test a next generation version of the AMDL ELISA DR-70 (FDP) colon
cancer monitoring test. (Successful completion of these studies could ... DR-70 (FDP) cancer test as the standard of care for the monitoring of colon
Develop and launch a ...
Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting
... Cancer Network (NCCN) announced updates to their Guidelines on colon
and Rectal Cancers that included the recommendation that a determination ... The American Cancer Society estimates that about 108,070 new cases of colon
cancer and 40,740 new cases of rectal cancer will be diagnosed in 2008. ...
ScinoPharm Granted US Patent for Novel Crystal Forms
... the new forms and methods of treating
metastatic carcinoma of the colon
or rectum using these new forms.
This patent is the ninth US ... drug most commonly used to treat
patients with metastatic carcinoma of the colon
or rectum, became generic in
the US in February 2008. Annual sales of the ...
InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
... the United States and is a term referring to cancer that develops
in the colon
or rectum. The American Cancer Society estimates that there
will be about 108,070 new cases of colon
cancer and 40,740 new cases of
rectal cancer in 2008 in the United States. ...
Large-scale genetic study sheds new light on lung cancer
... Adenomatosis polyposis coli (APC). Mutations of this gene are common in colon
Ephrin receptors A3 and A5 (EPHA3 and EPHA5), neurotrophin ... called MEK inhibitors, has produced promising results in mouse models of colon
Likewise, the TSP's finding that more than 30 percent of tumors ...
Pressure BioSciences, Inc. Provides Corporate Update
... Medicine on the use of PCT in identifying potential protein
biomarkers in colon
cancer samples, and guidance relative to forecasted
Q32008 and FY2008 ... the discovery of
several proteins that he and his colleagues have found in colon
samples using PCT that have not been previously found in similar ...
Genomic Health Announces Second Quarter 2008 Financial Results and Business Progress
... with aromatase inhibitors with the goal of reporting results this year.
Cancer -- Received first trial specimens for our clinical validation ... of that study;
the timing of a validation study for a potential assay for colon
the outcome of our study in Japan; our ability to develop a test ...
FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
... Earlier staging of primary tumors with metastases in the
liver, such as colon
cancer, may improve treatment decisions and, hence,
the survival rate. ... Last Accessed on 4/16/08.
(2) American Cancer Society. "Overview: colon
and Rectum Cancer: How
Many People Get Colorectal Cancer?" Available at
Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening
... innovative, online
educational campaign entitled: "It's Time To Challenge colon
Cancer: Do You
Have The Guts?" The campaign aims to increase compliance ... About Colorectal Cancer
Colorectal cancer, which refers to cancer of the colon
and rectum, is
expected to have caused approximately 52,000 deaths in the ...
Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
... in tumor tissues in animal models, with
significant affinity for lung and colon
tissues. These results strongly
support the potential treatment of these ... anticancer activity in animal models of
non-small cell lung cancer and colon
LOR-253 is currently in IND-enabling GLP toxicology studies, ...
Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation
... products will now be available to
radiologists across China."
is an advanced visualization workstation for CT
Colonography and combines ... scans to identify, measure
and analyze suspicious pathology within the colon
and lungs. The Medicsight
CAD products are validated against one of the ...
Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo
... with take-home colorectal
screening tests. Titled "It's Time to Challenge colon
Cancer: Do You Have
the Guts?," the campaign aims to break down barriers ... are found
"We are launching this campaign at the end of colon
Month because we want people to remember that this ...
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
... or that Anavex 7-1037 will
have the potential to treat melanoma, colon
cancer or other types of human
cancer or that Anavex 7-1037 will provide ... sigma ligands will
have the potential to be a new class of drugs to treat colon
other types of human cancer. Other risks that affect ...
Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
... with infusional 5-FU/LV, is indicated for adjuvant treatment of
stage III colon
cancer patients who have undergone complete resection of
the primary tumor, and is indicated for the treatment of advanced carcinoma
of the colon
or rectum. The product had sales of approximately $1.1 billion
in the ...
Medicsight Welcomes U.S. Initiative to Reimburse CT Colonography for Early Detection of Colorectal Cancer
... software use an advanced CAD
algorithm to analyse CT scans of the colon
and lung and automatically
highlight suspicious areas that may be ... The CTC exam is far less invasive than traditional methods
used to detect colon
and bowel diseases and patients do not require
sedation. Recent scientific ...
GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
... approval for an IVD ("in-vitro diagnostic")
version of the test.
Cancer and Screening
In the US, colon
cancer is the second leading cause of cancer deaths
for men and the third ...